Franziska Michor
Overview
Explore the profile of Franziska Michor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
195
Citations
10717
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McDonald T, Bruno S, Roney J, Zervantonakis I, Michor F
bioRxiv
. 2025 Feb;
PMID: 39975018
Understanding drug responses at the cellular level is essential for elucidating mechanisms of action and advancing preclinical drug development. Traditional dose-response models rely on simplified metrics, limiting their ability to...
2.
Riviere-Cazaux C, Graser C, Warrington A, Hoplin M, Andersen K, Malik N, et al.
Neuro Oncol
. 2025 Jan;
PMID: 39786485
Background: While serial sampling of glioma tissue is rarely performed prior to recurrence, cerebrospinal fluid (CSF) is an underutilized longitudinal source of candidate glioma biomarkers for understanding therapeutic impacts. However,...
3.
Cheng Y, Zhang Y, Tripathi S, Harshavardhan B, Jolly M, Schiebinger G, et al.
Proc Natl Acad Sci U S A
. 2024 Aug;
121(32):e2406842121.
PMID: 39093947
Exploring the complexity of the epithelial-to-mesenchymal transition (EMT) unveils a diversity of potential cell fates; however, the exact timing and mechanisms by which early cell states diverge into distinct EMT...
4.
Dean J, Reyes J, Tsabar M, Jambhekar A, Lahav G, Michor F
bioRxiv
. 2024 Jul;
PMID: 38979342
Genetically identical cells can respond heterogeneously to cancer therapy, with a subpopulation of cells often entering a temporarily arrested treatment-tolerant state before repopulating the tumor. To investigate how heterogeneity in...
5.
Riviere-Cazaux C, Graser C, Warrington A, Hoplin M, Andersen K, Malik N, et al.
medRxiv
. 2024 May;
PMID: 38798641
One Sentence Summary: Glioma cerebrospinal fluid (CSF) accessed intra-operatively and longitudinally via devices can reveal impacts of treatment and anatomical location.
6.
Janiszewska M, Tabassum D, Castano Z, Cristea S, Yamamoto K, Kingston N, et al.
Nat Cell Biol
. 2024 Mar;
26(5):841.
PMID: 38443568
No abstract available.
7.
Parra E, Zhang J, Duose D, Gonzalez-Kozlova E, Redman M, Chen H, et al.
Clin Cancer Res
. 2024 Jan;
30(8):1655-1668.
PMID: 38277235
Purpose: Identifying molecular and immune features to guide immune checkpoint inhibitor (ICI)-based regimens remains an unmet clinical need. Experimental Design: Tissue and longitudinal blood specimens from phase III trial S1400I...
8.
Liu Y, Altreuter J, Bodapati S, Cristea S, Wong C, Wu C, et al.
Cell Genom
. 2024 Jan;
4(1):100444.
PMID: 38190106
Immune checkpoint blockade (ICB) therapy targeting cytotoxic T-lymphocyte-associated protein 4, programmed death 1, and programmed death ligand 1 has shown durable remission and clinical success across different cancer types. However,...
9.
Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy
Kaczanowska S, Murty T, Alimadadi A, Contreras C, Duault C, Subrahmanyam P, et al.
Cancer Cell
. 2023 Dec;
42(1):35-51.e8.
PMID: 38134936
Chimeric antigen receptor T cells (CAR-Ts) have remarkable efficacy in liquid tumors, but limited responses in solid tumors. We conducted a Phase I trial (NCT02107963) of GD2 CAR-Ts (GD2-CAR.OX40.28.z.iC9), demonstrating...
10.
Sozen B, Flavell R, Lamming D, Silver D, Parrinello S, Abate-Shen C, et al.
Dev Cell
. 2023 Dec;
58(24):2822-2825.
PMID: 38113848
Researchers are leveraging what we have learned from model organisms to understand if the same principles arise in human physiology, development, and disease. In this collection of Voices, we asked...